Biotechs Pivot Under New Leadership

Galapagos's pivot into cell therapy was driven by the acquisitions of CellPoint and AboundBio for €125 million and $14 million, respectively. This move aims to leverage CellPoint's decentralized, automated point-of-care manufacturing model, which promises a 7-day turnaround for CAR-T therapies, and AboundBio's antibody-based platform for next-generation treatments. The goal is to bring three new CAR-T candidates to the clinic within three years. However, this strategic direction has seen recent upheaval with the announced departure of CEO Paul Stoffels and a reversal of the plan to spin off its drug development unit, with the company now exploring strategic alternatives for the cell therapy assets. Scorpius BioManufacturing's leadership transition involves appointing Gary Welch, a veteran with over 30 years of experience at firms like AbbVie and CytomX, as interim President. This move coincides with a significant capacity expansion, including new microbial capabilities at its San Antonio clinical-scale facility and plans for a new commercial-scale plant in Manhattan, Kansas. The expansion is designed to support both microbial and mammalian modalities, enabling clients to stay with Scorpius from early development through the entire product lifecycle. The turnarounds reflect a broader CDMO industry trend of aggressive expansion and specialization to meet surging demand, with the global market projected to reach $185 billion by the end of 2024. Companies are increasingly outsourcing to focus on core innovation, driving CDMOs to offer more than just capacity, requiring flexibility, speed, and advanced technical skills for complex modalities like cell and gene therapies. This demand is particularly strong for viral vector manufacturing and specialized oncology treatments. This operational agility is heavily reliant on digital transformation, a core tenet of Industry 4.0 in biomanufacturing. The use of digital twins—virtual replicas of manufacturing processes—is becoming critical for optimizing complex operations like cell culture and purification. By simulating processes in real-time using data from LIMS and MES, companies can predict outcomes, reduce validation efforts, and enhance process robustness without physical trial-and-error. In cell and gene therapy manufacturing, the data management challenge is immense, with a single batch record potentially containing over 3,000 data points. Electronic Batch Records (EBRs) are essential for managing this complexity, ensuring data integrity, and meeting GMP requirements. Integrating EBRs with LIMS and analytics platforms allows for real-time monitoring and leverages AI/ML to predict potential issues, a crucial step for accelerating development and ensuring the quality of viral vectors and other advanced therapies. However, viral vector manufacturing faces significant hurdles, including the need to increase capacity by one to two orders of magnitude to meet commercial demand. Key challenges involve scaling up from traditional adherent cell culture systems, which are labor-intensive and limit batch size, and improving purification processes to remove empty capsids that reduce efficacy. The industry is moving towards more scalable suspension-based systems and single-use technologies to address these bottlenecks.